---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Phase of product development"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Phase of product development. Topics: Investigational status and development phase, Regulatory status: Submission planned; NDA submission anticipated in 2028, Anticipated milestones: phase 3 topline data and study completion dates, Development history: phase 1/2 study start and status, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Investigational status and development phase

> “announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate, for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

> “Onvuzosiran is currently being evaluated in the Phase 3 STOP-HAE clinical trial ( NCT06960213 ).”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “have no products approved for commercial sale”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Submission planned; NDA submission anticipated in 2028

> “STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027. If STOP-HAE data are positive, we anticipate a potential New Drug Application (NDA) submission in 2028.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-3"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

### Anticipated milestones: phase 3 topline data and study completion dates

> “Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “STOP-HAE topline data expected by YE2027”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Primary Completion (Estimated) 2027-11-30”
> “Study Completion (Estimated) 2027-12-31”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Primary Completion (Estimated) 2030-06-30”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-2.1.1-5"></a>

### Development history: phase 1/2 study start and status

> “Study Start (Actual) 2022-12-14”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

> “today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

> “In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE.”
> “While patients continue to be dosed, given the reduction in HAE attack rate observed as of the August 19, 2026 data cutoff date, we believe sufficient safety, PK data and PD data have been collected to assess the primary and secondary objectives.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-6"></a>

### Development history: phase 3 and extension study start

> “In August 2025, we initiated our Phase 3 STOP-HAE clinical trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “October 22, 2025”
> “today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

> “Study Start (Actual) 2026-04-02”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-2.1.1-7"></a>

### FDA orphan drug designation

> “the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADX-324 for the treatment of patients with HAE”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

> “In October 2025, the FDA granted orphan drug designation to onvuzosiran for the treatment of patients with HAE.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="topic-2.1.1-8"></a>

### FDA Fast Track designation

> “In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to onvuzosiran for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “The benefits of Fast Track designation include opportunities for frequent meetings with the FDA to discuss trial design, development plans and data needed to support drug approval, as well as the ability to submit a New Drug Application (NDA) on a rolling basis, and eligibility for priority review, if relevant criteria are met.”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

<a id="topic-2.1.1-9"></a>

### FDA feedback on the phase 3 design

> “Positive feedback from FDA to move forward with Phase 3 STOP-HAE study.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “Per feedback from the FDA, HAE attacks before Day 22 will be excluded from primary endpoint analysis, consistent with the siRNA proposed mechanism of action.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-10"></a>

### Regulatory designations outside the United States

No evidence found.

<a id="topic-2.1.1-11"></a>

### Patent protection

> “We own one issued U.S. utility patent, four pending U.S. utility patent applications, and 20 pending patent applications in Australia, Brazil, Canada, Chile, China, Colombia, Europe, Hong Kong, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Peru, Singapore, South Africa, and Taiwan that contain claims directed to the onvuzosiran composition of matter and to methods of treating diseases of interest using onvuzosiran.”
> “Patents issuing from these applications, if any, are expected to expire in 2042 and 2044, respectively, excluding any additional term for patent term adjustment or patent term extension.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
